At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 26 enrolled
Drug / intervention
ADX-629 +1 moredrug
Likely dose
ADX-629 600 milligramsfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Double-Blind Clinical Trial to Assess the Interaction Between ADX-629 and Ethanol While Exploring the Safety, Tolerability, and Activity of ADX-629 in Subjects With Elevated Ethanol Levels
In Brief
A Phase 2 clinical trial evaluating ADX-629 and Placebo for Ethanol Intoxication. Completed, enrolled 26 participants across 1 site.
Detailed Summary
A Double-Blind Trial to Assess the Interaction Between ADX-629 and Ethanol While Exploring the Safety, Tolerability, and Activity of ADX-629 in Subjects With Elevated Ethanol Levels
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEthanol Intoxication
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20222023202420252026
Enrollment StartNov 2021
Primary CompletionMay 2022
First PostedAug 2022
TodayJul 2026
First PostedAug 4, 2022
Enrollment StartNov 15, 2021
Primary CompletionMay 29, 2022
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 3.9 years ago
Interventions
ADX-629drug
3 oral doses of ADX-629 600 milligrams
Placebodrug
3 oral doses of placebo